MOTIVATION LETTER Every day in a Nigerian pharmacy, a patient walks out without a prescription they need. The reasons are predictable: the pharmacy is out of stock, the pharmacist is unavailable, the cost of a clinic visit to renew a prescription is prohibitive. I have seen this pattern for years as a licensed pharmacist in Nigeria, and it is the problem my venture solves. Open Startup International Acceleration 2026 is the right programme to build that solution because it targets pre-revenue, pre-incorporation health-tech ventures operating in Africa, and it demands a committed founding team with regulatory literacy. I meet every condition. My venture is a telepharmacy platform that connects Nigerian patients with licensed pharmacists for prescription verification, refill management, and medication delivery. The core technical infrastructure is already built: a typed, multi-scale knowledge-graph architecture called psyche-twin that fuses prescription records, patient history, and pharmacist availability into a single append-only event log. A first-person conversational interface sits on top of that graph, allowing patients to interact in plain language. The system is pre-revenue and pre-incorporation, exactly matching the Pre-Seed Track. My PCN pharmacist license is the regulatory key that lets this platform operate legally in Nigeria, where telemedicine regulations require a licensed professional to verify every prescription transaction. Most health-tech founders in this space do not hold that license. I do. That is a structural advantage. My computational research background supports the venture directly. The Bayesian MCMC calibration I built for the CCT model in addiction neuroscience uses the same PyMC pipeline I now use to model patient adherence patterns and pharmacy inventory dynamics. The protein-language-model delta-embeddings I developed for TOPOLOGIX, predicting drug-resistance mutations with AUROC 0.804, taught me how to build production-grade ML pipelines that generalize across domains. The ergofluids project, where a pre-registered hypothesis failed its first real-data gate and I reported that failure directly rather than reframing it, taught me how to validate honestly. That discipline applies directly to product development. The programme asks for ventures operating primarily on the continent with potential for pan-African scalability. Nigeria has 500,000 registered pharmacists serving 220 million people, concentrated in urban centers. Rural patients routinely travel four hours for a prescription refill. The same regulatory and infrastructure gaps exist across Ghana, Kenya, and South Africa. The platform architecture is designed for multi-country deployment from day one. I am enrolled in the M.Sc. Digital Health programme at Hasso Plattner Institute in Germany starting Winter 2026/27. That programme gives me access to European health-tech regulatory frameworks and digital health validation methodologies that I will apply directly to the venture. I am available for full participation throughout the acceleration programme. SHORT ESSAY: VENTURE DESCRIPTION The venture is a telepharmacy platform for prescription-drug access in Nigeria. It solves a specific operational problem: a patient with a valid prescription from a doctor cannot fill it because the nearest pharmacy is out of stock, the pharmacist is unavailable for verification, or the cost of travel to a stocked pharmacy exceeds the cost of the medication itself. The platform works in three steps. First, a patient submits a prescription image and a description of their location and medication needs through a conversational interface. Second, the system matches the prescription against a real-time inventory database of partner pharmacies, verifies the prescription against regulatory requirements using a licensed pharmacist on the platform, and identifies the nearest pharmacy with stock. Third, the medication is delivered or made available for pickup, with the pharmacist available for follow-up consultation. The technical stack is already built. The core is psyche-twin, a typed multi-scale knowledge graph that stores every prescription, every pharmacist verification, every inventory update, and every patient interaction as an append-only event log. Disagreements between data streams, such as a patient reporting a side effect that contradicts the pharmacist's notes, become explicit graph edges rather than being averaged away. A first-person conversational interface built on top of the graph generates responses grounded in the current state of the system. Revenue model: a per-transaction fee on each prescription filled through the platform, paid by the pharmacy. The fee is lower than the cost of a missed sale. The platform does not handle medication itself, does not store drugs, and does not replace the pharmacist. It replaces the coordination problem. The venture is pre-revenue and pre-incorporation. The founding team is myself, a PCN-licensed pharmacist with a B.Pharm from the University of Ibadan and current enrollment in the M.Sc. Digital Health programme at Hasso Plattner Institute. I have built the technical infrastructure independently. I am seeking incorporation in Nigeria and the first pilot deployment in Lagos State within six months of programme completion. SHORT ESSAY: FOUNDER BACKGROUND AND RELEVANCE I am a pharmacist, a computational modeler, and a software engineer. These three identities converge directly on the telepharmacy venture. As a pharmacist, I hold a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9. I am licensed by the Pharmacists Council of Nigeria. I worked as a clinical pharmacist at Ramset Pharmacy from January to March 2026, and I currently serve as National Product Manager at Synthcare, a pharmaceutical distribution company. I understand the operational reality of Nigerian pharmacy: the stockouts, the regulatory paperwork, the patient who cannot afford the clinic visit to renew a prescription. As a computational modeler, I have built and validated complex systems across multiple domains. The CCT model, a tripartite pharmacological framework for reward-memory encoding prevention in addiction, uses a coupled three-axis ODE system with Bayesian MCMC calibration on 14 free parameters. All five pre-registered hypotheses were confirmed. The TOPOLOGIX project predicts drug-resistance mutations from protein sequence alone, achieving AUROC 0.804 on the Platinum benchmark, beating structure-based baselines while covering 100 percent of mutations versus roughly 18 percent for structure-limited tools. The ergofluids project applied Koopman-operator methods to model drug transport through tumor tissue; when the first real-data gate failed its pre-registered criterion, I reported that failure directly. That discipline in validation is what I bring to product development. As a software engineer, I have built four independent DuckDB-based ingest-to-analyze pipelines across life sciences, tech and AI security, and social science domains. I self-host local LLM serving with llama.cpp and on-demand model swapping. I run production systems on Linux VPS with systemd, Caddy TLS, CI/CD, and automated backup and disaster-recovery. The telepharmacy platform's knowledge-graph architecture is already deployed and functional. The programme asks for ventures in health and well-being. My venture is exactly that. The programme asks for a committed founding team. I am that team. The programme asks for potential for pan-African scalability. The platform is designed for it. RESEARCH STATEMENT My research programme spans addiction neuroscience, protein machine learning, and dynamical-systems methods. It is unified by a single methodological commitment: build a model, pre-register the hypotheses, test them honestly, and report the results regardless of outcome. This discipline is what I bring to the telepharmacy venture. The CCT model, or Conjunctive Consolidation Threshold model, is a tripartite pharmacological framework for preventing reward-memory encoding in addiction. It couples three axes: dopaminergic reward prediction error, NMDAR-dependent long-term potentiation, and affective contrast. The system is a set of ordinary differential equations solved with RK45, calibrated with Bayesian MCMC using PyMC's DEMetropolisZ sampler on 14 free parameters. The priors came from a literature screen of 1,847 records. All five pre-registered hypotheses, H1 through H5, were confirmed. Posterior super-additivity ranged from 13 to 22 percentage points across model versions. Three sole-authored preprints are under review at peer-reviewed journals: IART, PNPBP, and NBR. A co-authored paper is under review at Alcohol, Elsevier. The TOPOLOGIX project shifted my focus to protein-drug interactions. I tested whether bipartite persistent homology could predict hERG cardiotoxicity from protein-ligand interface geometry. The pre-registered, powered replication found that topological features do not beat a plain descriptor baseline: AUROC 0.8426 versus 0.8782. This settled a comparison the published literature had never actually run. I then applied the same topological constructs to drug-resistance prediction and found they carried almost no signal: AUROC 0.425 and 0.485 on the Platinum benchmark. That negative result ruled out interface geometry as the driver and motivated a sequence-representation approach. TOPOLOGIX uses ESM-2 protein-language-model delta-embeddings plus Morgan and ECFP drug fingerprints with a Random Forest classifier. It achieves AUROC 0.804 plus or minus 0.025 on the Platinum benchmark, covering 553 mutations, and 0.634 on SKEMPI 2.0. It beats structure-based baselines like mCSM-lig at roughly 0.70 while covering 100 percent of mutations versus roughly 18 percent for structure-limited tools. The neurocascade project is a receptor-to-behavior brain-circuit simulation engine. It couples pharmacokinetics to receptor-binding to Wilson-Cowan circuit dynamics to behavioral-readout ODE layers. Three literature-calibrated receptor and circuit systems, mu-opioid, D2 dopamine, and GABA-A, are Bayesian-calibrated with PyMC. All 62 tests pass. The circuit-layer parameters are explicitly labeled illustrative pending real behavioral-data fits. The ergofluids project extended Koopman-operator and Dynamic Mode Decomposition methods with a Mori-Zwanzig memory kernel to model macromolecular drug-vehicle transport through dense, non-Newtonian tumor tissue. The pre-registered gated validation pipeline passed synthetic-data gates. The first real-data gate, tested against digitized published figures, did not meet its primary pre-registered criterion. I reported that directly rather than reframing it. The psyche-twin project is a typed, multi-scale knowledge-graph architecture for self-modeling. Multiple independent evidence streams, including LLM-derived, assessment-derived, behavioral, and document-derived, fuse into one append-only event log. Disagreement between streams becomes an explicit graph edge rather than being averaged away. A first-person conversational interface sits on top of the graph, generating responses grounded in the graph's current state. This is the architecture that powers the telepharmacy venture. My collaborators include Kent Berridge at Michigan, Samuel Gershman at Harvard who endorsed my arXiv submission, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. These are researchers who hold their own work to the same standard of pre-registration and honest reporting. CHECKLIST - [ ] Motivation letter, 300-500 words, written as first-person applicant - [ ] Short essay: venture description, 200-350 words - [ ] Short essay: founder background and relevance, 200-350 words - [ ] Research statement, 400-600 words - [ ] Pitch deck, 10-15 slides, PDF format - [ ] Business plan or executive summary, 2-3 pages, PDF format - [ ] Team information document, 1 page, listing founder and any advisors - [ ] Proof of incorporation or registration in an African country (to be obtained before submission) - [ ] Completed application form on the Menterprise Africa platform - [ ] Copy of PCN pharmacist license for verification - [ ] Proof of enrollment or acceptance into M.Sc. Digital Health at Hasso Plattner Institute EDITOR NOTES - Eligibility risk: the programme requires proof of incorporation or registration in an African country. Eniola is pre-incorporation. She must either register a business in Nigeria before the July 31 deadline or confirm with the programme that pre-incorporation ventures are accepted. The deep research says proof of incorporation is required for application. This is a hard gate. - Fact to verify: the programme URL points to Menterprise Africa, but the provider name is not listed in the profile. Confirm the exact provider name and any additional eligibility conditions not captured in the deep research. - Gap: the profile does not specify the telepharmacy venture's name. The applicant must insert a venture name in the motivation letter and short essays. The placeholder "the venture" should be replaced with the actual name. - Gap: the profile does not specify whether Eniola has a co-founder or advisory board. The programme asks for a committed founding team. If she is solo, she should state that explicitly and explain how she will meet the programme's participation requirements. - Verification needed: the deep research states the programme has a Pre-Seed Track and a Seed Track. Confirm which track Eniola is applying to and that the venture's stage matches the track's requirements. The profile says pre-revenue and pre-incorporation, which fits Pre-Seed, but the programme's own materials should be checked.